Hospitalized COVID patients are being treated with Actemra (tocilizumab) causing a supply shortage impacting patients internationally. This ongoing ripple effect means that once again, AiArthritis and other high-risk patients are forced to deal with another wave of complications in managing their health because of COVID. This time in risking long term health due to lack of adequate treatment, along with unnecessary pain and anxiety. Unfortunately, in some cases, these risks and complications could have been prevented.
Autoimmune and Autoinflammatory Diseases that include inflammatory arthritis as a significant clinical component (AiArthritis Diseases) are full-body conditions affecting joints, tissues, and organs. Given these diseases are unique per individual, finding the right treatment can take months or years.
Autoimmune and Autoinflammatory Diseases that include inflammatory arthritis as a significant clinical component (AiArthritis Diseases) are full-body conditions affecting joints, tissues, and organs. Given these diseases are unique per individual, finding the right treatment can take months or years.
Most patients are prescribed disease-modifying antirheumatic drugs (DMARDs), including biologics, to manage their condition, but there’s no one-size-fits-all therapy, and responses vary per individual. The right therapy can be life-changing; disrupting continuity of care is strongly discouraged, as it can result in compromised quality of life, loss of employment, and comorbid diseases.
But to accommodate hospital inventory needs due to high COVID hospitalization rates, mostly attributed to those not vaccinated , chronically ill rheumatology patients worldwide are being forced off their treatments…and they are angry.
Erin (USA), diagnosed age 14 with juvenile Psoriatic Arthritis, says, “Throughout the pandemic the public was asked to protect the at-risk population by washing their hands, socially distancing, wearing a mask, and getting vaccinated. Now the ‘at-risk’ people must protect some who didn’t do their part?”
Bottom line: This situation was, and still can be, preventable. If more people choose vaccination, hospitalization rates would decrease, and rheumatology patients may not be forced to sacrifice the treatments that work best for them.
Tell us about it.
Thank you for telling us how Actemra Shortage has impacted you! If you have any questions, please contact us at info@aiarthritis.org
Oops, there was an error in sending your message.
Please try again! Or you can reach out to us at info@aiarthritis.org
Deb, Tiffany and Katie discuss making informed decisions in the age of COVID-19, and the impact of those choices. A focus on the Actemra shortage and how this impacts our community.
International Foundation for AiArthritis
6605 Nottingham Ave.
St. Louis, MO 63109-2661
Tax ID: 27-1214308
Copyright 2024. All rights reserved. Information on this site is intended for informational purposes only Our foundation does not engage in the practice of medicine. Please consult a physician to obtain personal healthcare and treatment options. 501(c) 3 Nonprofit Tax ID: 27-1214308.